Nose-to-brain delivery of empagliflozin-loaded nanostructured lipid carriers incorporated in-situ gel: Biopharmaceutical evaluation for Alzheimer’s disease
European Journal of Pharmaceutics and Biopharmaceutics · 2026-09 · 226 · 115161
DOI: 10.1016/j.ejpb.2026.115161 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026-09. Verfasst von Kalyani Puranik und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, STES's Sinhgad College of Pharmacy (Affiliated to Savitribai Phule Pune University), Vadgaon (Bk.), Pune 411041, Maharas…. Hauptthemen laut MEDLINE: Alzheimer Disease, Drug Carriers, Nanostructures, Lipids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 88 Literaturangaben. Gefördert von: National Centre for Cell Science.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's therapy remains limited by poor drug targeting and multifactorial pathology. The therapeutic potential of SGLT-2 inhibitors like empagliflozin (EGZ) is constrained by poor brain bioavailability. Current study investigates the potential of EGZ-nanostructured lipid carrier (ENLC) for brain delivery via nasal route. The ENLC were prepared using hot melt emulsification technique followed by probe sonication and optimized using Box-Behnken design. ENLC were incorporated into poloxamer 407-chitosan in situ gel (ENPCG) to improve nasal retention, controlled release, and direct brain transport via olfactory and trigeminal uptake. ENPCG demonstrated a sustained drug release of 56.36 ± 3.37 % and enhanced nasal permeation. Nasal kinetics revealed high Cmaxmucosa (48.2 ± 1.42 µg/cm2) relative to plain EGZ-suspension (15.9 ± 0.7 µg/cm2) in goat nasal mucosa. ENPCG significantly improved cognitive memory in sporadic AD model, as confirmed by behavioural, biochemical, and histopathological assessments in Wistar rats. Pharmacokinetic study in Sprague Dawley rats revealed a 4.5-fold increase in AUC0-t of intranasal ENPCG (30.56 ± 0.45 μg/mL*h) relative to intravenous ENLC (6.73 ± 0.15 μg/mL*h). ENPCG showed 95.31 ± 3.89 % drug targeting potential. Furthermore, a strong point-to-point ex vivo-in vivo correlation (R2 = 0.9952) was observed, suggesting a non-invasive potential of ENPCG for translating AD interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, STES's Sinhgad College of Pharmacy (Affiliated to Savitribai Phule Pune University), Vadgaon (Bk.), Pune 411041, Maharashtra, India. Electronic address: kalyanikayande.siop@sinhgad.edu.
- Department of Pharmaceutics, STES's Sinhgad College of Pharmacy (Affiliated to Savitribai Phule Pune University), Vadgaon (Bk.), Pune 411041, Maharashtra, India.
- Department of Pharmaceutics, Marathwada Mitra Mandal's College of Pharmacy (Affiliated to Savitribai Phule Pune University), Thergaon (Kalewadi), Pune 411 0331, Maharashtra, India.
- Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai 400019, Maharashtra, India.
Förderung
- National Centre for Cell Science
Zitieren
APA
Puranik, K., Ranpise, N., Khot, S., & Negi, P. (2026). Nose-to-brain delivery of empagliflozin-loaded nanostructured lipid carriers incorporated in-situ gel: Biopharmaceutical evaluation for Alzheimer’s disease. European Journal of Pharmaceutics and Biopharmaceutics, 226, 115161. https://doi.org/10.1016/j.ejpb.2026.115161
Vancouver
Puranik K, Ranpise N, Khot S, Negi P. Nose-to-brain delivery of empagliflozin-loaded nanostructured lipid carriers incorporated in-situ gel: Biopharmaceutical evaluation for Alzheimer’s disease. European Journal of Pharmaceutics and Biopharmaceutics. 2026;226:115161. doi:10.1016/j.ejpb.2026.115161
BibTeX
@article{Puranik2026,
author = {Puranik, Kalyani and Ranpise, Nisharani and Khot, Shubham and Negi, Preeya},
title = {Nose-to-brain delivery of empagliflozin-loaded nanostructured lipid carriers incorporated in-situ gel: Biopharmaceutical evaluation for Alzheimer’s disease},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2026},
volume = {226},
pages = {115161},
doi = {10.1016/j.ejpb.2026.115161}
}
EUVIMED